ClearBridge Investments’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.19M Buy
22,625
+385
+2% +$20.4K ﹤0.01% 626
2026
Q1
$1.23M Buy
22,240
+4,001
+22% +$217K ﹤0.01% 620
2025
Q4
$894K Hold
18,239
﹤0.01% 644
2025
Q3
$787K Sell
18,239
-8,029
-31% -$314K ﹤0.01% 665
2025
Q2
$1.01M Sell
26,268
-413
-2% -$15.8K ﹤0.01% 638
2025
Q1
$1.03M Hold
26,681
﹤0.01% 636
2024
Q4
$902K Hold
26,681
﹤0.01% 648
2024
Q3
$1.09M Sell
26,681
-673
-2% -$27.5K ﹤0.01% 643
2024
Q2
$1.05M Hold
27,354
﹤0.01% 669
2024
Q1
$1.17M Sell
27,354
-2,942
-10% -$121K ﹤0.01% 658
2023
Q4
$1.12M Sell
30,296
-32
-0.1% -$1.15K ﹤0.01% 660
2023
Q3
$1.1M Hold
30,328
﹤0.01% 620
2023
Q2
$1.08M Hold
30,328
﹤0.01% 626
2023
Q1
$1.08M Sell
30,328
-1,589
-5% -$55.6K ﹤0.01% 641
2022
Q4
$1.12M Hold
31,917
﹤0.01% 660
2022
Q3
$939K Sell
31,917
-1
-0% -$38 ﹤0.01% 674
2022
Q2
$1.74M Buy
31,918
+7,464
+31% +$412K ﹤0.01% 649
2022
Q1
$1.33M Buy
24,454
+481
+2% +$26.1K ﹤0.01% 693
2021
Q4
$1.32M Hold
23,973
﹤0.01% 702
2021
Q3
$1.15M Sell
23,973
-373
-2% -$18.7K ﹤0.01% 696
2021
Q2
$1.21M Sell
24,346
-552
-2% -$26.5K ﹤0.01% 697
2021
Q1
$1.11M Buy
24,898
+25
+0.1% +$1.14K ﹤0.01% 676
2020
Q4
$1.14M Sell
24,873
-1,864
-7% -$85.6K ﹤0.01% 663
2020
Q3
$1.26M Sell
26,737
-4
-0% -$200 ﹤0.01% 639
2020
Q2
$1.36M Sell
26,741
-1,016
-4% -$52.1K ﹤0.01% 612
2020
Q1
$1.31M Buy
27,757
+6,703
+32% +$358K ﹤0.01% 605
2019
Q4
$1.24M Buy
21,054
+685
+3% +$38.1K ﹤0.01% 646
2019
Q3
$1.09M Sell
20,369
-46,541
-70% -$2.39M ﹤0.01% 661
2019
Q2
$3.35M Sell
66,910
-23,372
-26% -$1.17M ﹤0.01% 600
2019
Q1
$4.72M Sell
90,282
-1,824
-2% -$91.1K ﹤0.01% 583
2018
Q4
$4.4M Buy
92,106
+16,230
+21% +$799K ﹤0.01% 594
2018
Q3
$3.81M Sell
75,876
-3,056
-4% -$155K ﹤0.01% 609
2018
Q2
$3.98M Sell
78,932
-20,079
-20% -$1.01M ﹤0.01% 534
2018
Q1
$4.83M Sell
99,011
-103
-0.1% -$4.8K ﹤0.01% 515
2017
Q4
$4.39M Sell
99,114
-96,728
-49% -$4.47M ﹤0.01% 527
2017
Q3
$9.94M Sell
195,842
-1,928
-1% -$97.8K 0.01% 483
2017
Q2
$10.7M Sell
197,770
-1,183
-0.6% -$63.1K 0.01% 474
2017
Q1
$10.5M Sell
198,953
-261,583
-57% -$13.3M 0.01% 483
2016
Q4
$22.2M Sell
460,536
-13,373
-3% -$661K 0.02% 391
2016
Q3
$25.6M Sell
473,909
-148,020
-24% -$8.12M 0.03% 382
2016
Q2
$33.7M Sell
621,929
-6,826
-1% -$360K 0.04% 331
2016
Q1
$31.9M Sell
628,755
-767,724
-55% -$38.2M 0.04% 341
2015
Q4
$70.4M Sell
1,396,479
-63,603
-4% -$3.24M 0.08% 219
2015
Q3
$70.2M Sell
1,460,082
-80,433
-5% -$4.19M 0.08% 220
2015
Q2
$80.2M Sell
1,540,515
-500,046
-25% -$28.2M 0.08% 212
2015
Q1
$118M Buy
2,040,561
+202,807
+11% +$11.6M 0.12% 175
2014
Q4
$98.2M Sell
1,837,754
-106,922
-5% -$5.98M 0.1% 194
2014
Q3
$112M Sell
1,944,676
-14,839
-0.8% -$910K 0.12% 169
2014
Q2
$131M Sell
1,959,515
-81,699
-4% -$5.53M 0.15% 154
2014
Q1
$136M Buy
2,041,214
+4,489
+0.2% +$303K 0.16% 151
2013
Q4
$136M Sell
2,036,725
-617,522
-23% -$40M 0.17% 151
2013
Q3
$166M Sell
2,654,247
-40,720
-2% -$2.62M 0.23% 123
2013
Q2
$168M Buy
+2,694,967
New +$171M 0.26% 116

Other funds holding GSK

ClearBridge Investments's GSK Position: Q2 2026 in Review

ClearBridge Investments increased its GSK (GSK) stake by 1.7% in Q2 2026, buying an estimated $20.4K and bringing the position to 22,625 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #626.

ClearBridge Investments first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $168M in Q2 2013. 878 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • ClearBridge Investments held 22,625 shares of GSK worth $1.19M as of Q2 2026.
  • ClearBridge Investments bought 385 GSK shares in Q2 2026, an estimated $20.4K.
  • GSK made up ﹤0.01% of ClearBridge Investments's portfolio in Q2 2026, its #626 holding.
  • ClearBridge Investments first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • ClearBridge Investments's GSK position peaked at $168M in Q2 2013.
  • 878 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.